GRYPHON BIO

OUR STORY

Gryphon Bio is a clinical stage company created to harness our co-founders' discovery, over more than 20 years of -omic research, of unexpected waves of 1000s of brain molecules in the blood. The levels of brain-specific molecules in the blood change over time, like waves in the ocean, and can serve as biomarkers for novel blood tests of brain health.

OUR MISSION

Gryphon designs, develops, validates, and manufactures high quality clinical blood tests for innovative brain biomarkers to monitor the patient journey. This is performed in compliance with all applicable regulatory requirements. Together with our clinical testing laboratory partners, this promises to transform the care and treatment of patients by healthcare professionals to unlock clinical insights and improve patient outcomes.

OUR VISION

Gryphon seeks to provide novel blood tests to monitor the patient journey, including childhood and adult patients as well as civilian, military, and veteran patients. Our focus is initially on traumatic brain injury, Alzheimer’s disease, and adjacent brain conditions. We envision a future when insights from Gryphon’s blood tests improve the care and treatment of patients with a variety of indications and provide molecular Evidence of Brain Health (mEBH) - including recovery and healthy aging. In doing so, Gryphon endeavors to create value for our clinical laboratory customers, prescribing physicians and other caregivers, affiliated hospitals, payors, and researchers.

OUR PIPELINE

Clinical Studies

We closely engage with our courageous patients to assess needs and to improve our blood tests for early disease detection and monitoring of brain health. Results from blood tests will be used by care providers to inform on key decisions such as recovery, hospitalization, and return-to-work/play/duty.

Partnering

Our novel blood tests for brain health can also enrich and track patients responding to various drugs. This de-risks and accelerates our partners' drug discovery and development workflows, thereby increasing the likelihood of achieving successful outcomes in clinical trials and regulatory approvals.

OUR COURAGEOUS PATIENTS

Brain health is affected by a number of CNS diseases, including:

Traumatic Brain Injury (TBI)
Alzheimer's disease (AD)
Mild Cognitive Impairment (MCI)

OUR INVESTORS

$13M

Non-Dilutive Funding

(Grant Awards & Contracts)

$0.65M

Total Cash Raised

Investment Opportunities

OUR COURAGEOUS TEAM

We are a proven, cohesive, interdisciplinary and internationally recognized team with deep experience in blood test development.

View Bio

WILL HASKINS, PHD

CEO & Co-Founder

View Bio

KEVIN WANG, PHD

Co-Founder & Chair of Scientific Advisory Board

View Bio

ANTHONY DELIZZA, MS

Chief Business Officer

View Bio

View Bio

DEVIN JACKSON, PHD

Senior Research Scientist

View Bio

KRISTY RADEKER, MSM

Associate Director, Clinical Operations & Finance

View Bio

KATIE TEHAS

Research Associate

View Bio

If you want to learn more about our amazing team members, get in touch.

OUR LATEST NEWS

What's New

Check our news section on a regular basis to always stay in the loop.

14. Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's Disease

January 13, 2025

SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ -- Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and international clinical sites to demonstrate the benefits of a novel panel of blood biomarkers for early detection and monitoring of traumatic brain injury (TBI) and Alzheimer's disease (AD). Combined with known risk factors, such as age and genetic variants, the Gryphon Bio studies are potential game-changers to monitor the treatment journey and develop novel therapeutics for active-duty soldiers, Veterans, adults, and children worldwide who suffer from this devastating disease.

"TBI is an established risk factor for dementia and Parkinson's disease. Innovative biomarker studies at the interface of these and related disorders are critical to rapidly develop pragmatic tests to aid patients, caregivers, and providers in making informed care decisions today and to guide precision-medicine treatments in the future," said Dr. Raquel Garner, Director of Clinical Research, Sago Neuroscience Center, Sheba Medical Center.

"TBI remains one of the leading causes of death and disability among children, as well as adults, worldwide. New blood tests for TBI will empower physicians as an aid-in-monitoring in pre-hospital, hospital, and post-hospital care settings to support clinical decisions based on this and other clinical assessments. It is time to prioritize innovative solutions to address this global brain health crisis," said Dr. Todd Kilbaugh, MD Director of the Resuscitation Science Center and Endowed Chair of Translational Science and Innovation, The University of Pennsylvania and The Children's Hospital of Philadelphia.

Gryphon also announces the appointment of Anthony DeLizza as Chief Business Officer responsible for the oversight of Gryphon's biomarker validation studies, product development, FDA product clearance, and commercialization. Mr. DeLizza has a long career commercializing med-tech solutions including laboratory, point-of-care diagnostics and medical devices. He previously held positions at Syva Company (now Dade-Behring Diagnostics, Siemens), Johnson & Johnson, and a variety of diagnostic and medical device companies.

Gryphon's novel blood tests for unexpected waves of 1000s of brain biomarkers (and therapeutic targets) in the blood of TBI patients. These novel biomarkers were discovered after more than 22 years of proteomic research by Gryphon's co-founders, Drs. William E. Haskins and Kevin Wang. Gryphon is backed by $13M+ in non-dilutive government grant awards and contracts

Media Enquiries:
bd@gryphonbio.com

Learn More